Triple-Drug cocktail aims to reverse early heart disease
NCT ID NCT07474649
First seen Jun 25, 2026 · Last updated Jul 24, 2026 · Updated 3 times
Summary
This Phase 3 trial will test whether a combination of three cholesterol-lowering drugs—bempedoic acid, ezetimibe, and a high-intensity statin—can reduce and stabilize plaque buildup in the coronary arteries. The study enrolls 103 adults with coronary atherosclerosis who have never had a heart attack or stroke and are not on any lipid-lowering treatment. Participants will take the triple therapy for one year, and changes in plaque burden will be measured using imaging.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- bempedoic acid, ezetimibe, and a high-intensity statin (atorvastatin or rosuvastatin)
- What this could lead to
- If successful, this could show that a triple-drug combination reduces coronary plaque burden and stabilizes plaque, potentially lowering future heart attack risk in people with early atherosclerosis.
- What could go wrong
- This is a small Phase 3 trial (103 participants) that has not yet started recruiting. The results may not apply to broader populations, and the combination therapy may cause side effects like muscle pain or liver issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONARY ATHEROSCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a daily pill help kids with inherited high cholesterol?
- Free meds and tailored education may cut heart risks in Low-Income seniors
- Can a smartphone app help lower bad cholesterol?
- New cholesterol drug candidate tested in healthy volunteers
- Weight-Loss drug may also protect heart arteries
- New cholesterol drugs show promise in Late-Stage trial